IBDEI0YL ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,15620,1,4,0)
 ;;=4^E11.65
 ;;^UTILITY(U,$J,358.3,15620,2)
 ;;=^5002663
 ;;^UTILITY(U,$J,358.3,15621,0)
 ;;=E11.649^^61^760^21
 ;;^UTILITY(U,$J,358.3,15621,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15621,1,3,0)
 ;;=3^DM Type 2 Uncontrolled w/ Hypoglycemia w/o Coma
 ;;^UTILITY(U,$J,358.3,15621,1,4,0)
 ;;=4^E11.649
 ;;^UTILITY(U,$J,358.3,15621,2)
 ;;=^5002662
 ;;^UTILITY(U,$J,358.3,15622,0)
 ;;=I16.0^^61^760^44
 ;;^UTILITY(U,$J,358.3,15622,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15622,1,3,0)
 ;;=3^Hypertensive Urgency
 ;;^UTILITY(U,$J,358.3,15622,1,4,0)
 ;;=4^I16.0
 ;;^UTILITY(U,$J,358.3,15622,2)
 ;;=^8133013
 ;;^UTILITY(U,$J,358.3,15623,0)
 ;;=H54.8^^61^760^47
 ;;^UTILITY(U,$J,358.3,15623,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15623,1,3,0)
 ;;=3^Legal Blindness,USA Definition
 ;;^UTILITY(U,$J,358.3,15623,1,4,0)
 ;;=4^H54.8
 ;;^UTILITY(U,$J,358.3,15623,2)
 ;;=^5006369
 ;;^UTILITY(U,$J,358.3,15624,0)
 ;;=F10.10^^61^760^2
 ;;^UTILITY(U,$J,358.3,15624,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15624,1,3,0)
 ;;=3^Alcohol Abuse,Uncomplicated
 ;;^UTILITY(U,$J,358.3,15624,1,4,0)
 ;;=4^F10.10
 ;;^UTILITY(U,$J,358.3,15624,2)
 ;;=^5003068
 ;;^UTILITY(U,$J,358.3,15625,0)
 ;;=J30.9^^61^760^3
 ;;^UTILITY(U,$J,358.3,15625,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15625,1,3,0)
 ;;=3^Allergic Rhinitis,Unspec
 ;;^UTILITY(U,$J,358.3,15625,1,4,0)
 ;;=4^J30.9
 ;;^UTILITY(U,$J,358.3,15625,2)
 ;;=^5008205
 ;;^UTILITY(U,$J,358.3,15626,0)
 ;;=I48.0^^61^760^7
 ;;^UTILITY(U,$J,358.3,15626,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15626,1,3,0)
 ;;=3^Atrial Fibrillation Paroxysmal (PAF)
 ;;^UTILITY(U,$J,358.3,15626,1,4,0)
 ;;=4^I48.0
 ;;^UTILITY(U,$J,358.3,15626,2)
 ;;=^90473
 ;;^UTILITY(U,$J,358.3,15627,0)
 ;;=N18.1^^61^760^9
 ;;^UTILITY(U,$J,358.3,15627,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15627,1,3,0)
 ;;=3^CKD,Stage 1
 ;;^UTILITY(U,$J,358.3,15627,1,4,0)
 ;;=4^N18.1
 ;;^UTILITY(U,$J,358.3,15627,2)
 ;;=^5015602
 ;;^UTILITY(U,$J,358.3,15628,0)
 ;;=N18.2^^61^760^10
 ;;^UTILITY(U,$J,358.3,15628,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15628,1,3,0)
 ;;=3^CKD,Stage 2
 ;;^UTILITY(U,$J,358.3,15628,1,4,0)
 ;;=4^N18.2
 ;;^UTILITY(U,$J,358.3,15628,2)
 ;;=^5015603
 ;;^UTILITY(U,$J,358.3,15629,0)
 ;;=N18.4^^61^760^14
 ;;^UTILITY(U,$J,358.3,15629,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15629,1,3,0)
 ;;=3^CKD,Stage 4
 ;;^UTILITY(U,$J,358.3,15629,1,4,0)
 ;;=4^N18.4
 ;;^UTILITY(U,$J,358.3,15629,2)
 ;;=^5015605
 ;;^UTILITY(U,$J,358.3,15630,0)
 ;;=N18.5^^61^760^15
 ;;^UTILITY(U,$J,358.3,15630,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15630,1,3,0)
 ;;=3^CKD,Stage 5
 ;;^UTILITY(U,$J,358.3,15630,1,4,0)
 ;;=4^N18.5
 ;;^UTILITY(U,$J,358.3,15630,2)
 ;;=^5015606
 ;;^UTILITY(U,$J,358.3,15631,0)
 ;;=N18.6^^61^760^26
 ;;^UTILITY(U,$J,358.3,15631,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15631,1,3,0)
 ;;=3^ESRD
 ;;^UTILITY(U,$J,358.3,15631,1,4,0)
 ;;=4^N18.6
 ;;^UTILITY(U,$J,358.3,15631,2)
 ;;=^303986
 ;;^UTILITY(U,$J,358.3,15632,0)
 ;;=E11.22^^61^760^22
 ;;^UTILITY(U,$J,358.3,15632,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15632,1,3,0)
 ;;=3^DM Type 2 w/ CKD
 ;;^UTILITY(U,$J,358.3,15632,1,4,0)
 ;;=4^E11.22
 ;;^UTILITY(U,$J,358.3,15632,2)
 ;;=^5002630
 ;;^UTILITY(U,$J,358.3,15633,0)
 ;;=E11.319^^61^760^24
 ;;^UTILITY(U,$J,358.3,15633,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,15633,1,3,0)
 ;;=3^DM Type 2 w/ Retinopathy Unspec w/o Macular Edema
